Press Release: Galen Partners : Galen Partners Completes Sale of Cambrooke Therapeutics

Galen Partners, a healthcare-focused, growth equity investment firm, announced today the sale of Cambrooke Therapeutics, Inc. (“Cambrooke”) to Ajinomoto Co. Cambrooke is a global leader and innovator in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy. Cambrooke’s product portfolio serves the needs of people with chronic health conditions reliant on Medical Foods and specialized functional foods as a central component of their daily nutritional needs. Zubeen Shroff, Managing Director of Galen Partners, remarked that “with this acquisition, Cambrooke gains access to Ajinomoto’s global nutrition and ingredient sciences expertise, and will continue leading the field of therapeutic nutrition solutions for chronic health conditions and serving its customers’ lifestyle needs, now with expanded reach and R&D capabilities”.